BLCM Bellicum Pharmaceuticals Inc.

1.1
+0.06  (+6%)
Previous Close 1.04
Open 1.05
Price To Book 0.74
Market Cap 50,879,579
Shares 46,254,163
Volume 547,751
Short Ratio
Av. Daily Volume 779,436

NewsSee all news

  1. Bellicum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    HOUSTON, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today

  2. Bellicum Pharmaceuticals to Participate in Three Healthcare Investor Conferences during September

    HOUSTON, Aug. 28, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 pediatric top-line data met primary endpoint of event free survival - July 8, 2019.
BPX-501 Rivo-cel
Adjunct T-cell therapy administered after allogeneic HSCT - (hematopoietic stem cell transplantation) - cancer
Phase 1 further data due 4Q 2019 or 1Q 2020.
BPX-601
Pancreatic cancer
Phase 2/3 ongoing.
Rivo-cel -THRIVE
Acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS)

Latest News

  1. Bellicum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    HOUSTON, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today

  2. Bellicum Pharmaceuticals to Participate in Three Healthcare Investor Conferences during September

    HOUSTON, Aug. 28, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today